Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00857350 · ClinicalTrials.gov registry record
The Prevalence of HIV Drug Resistance and Transmission Risk in Opioid Agonist Treatment
A clinical trial, sponsored by Yale University.
- Completed
- Registry status
- 60
- Enrollment target
NCT00857350 is a clinical trial that has completed, run by Yale University. The registered enrollment target is 60 participants.
The verdict
NCT00857350 has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- 60 participants
- Enrollment target
Study Summary
HIV drug resistance presents a significant public heath problem. This proposal is designed to explore the association between ongoing illicit drug use and the prevalence of HIV drug resistance among HIV+ opioid dependent patients receiving opioid agonist treatment with the following hypotheses: 1. Hypothesis 1: The prevalence of HIV drug resistance will range between 10% and 30%. 2. Hypothesis 2: Patients with evidence of ongoing illicit drug use will be more likely to have HIV drug resistance.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2008-06 |
| Est. Completion | 2012-09 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00857350
The ClinicalTrials.gov registry entry for NCT00857350 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT00857350 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00857350 about?
NCT00857350 is a clinical study titled "The Prevalence of HIV Drug Resistance and Transmission Risk in Opioid Agonist Treatment". HIV drug resistance presents a significant public heath problem. This proposal is designed to explore the association between ongoing illicit drug use and the prevalence of HIV drug resistance among HIV+ opioid dependent patients receiving opioid agonist treatment with the following hypotheses: 1. ...
What is the current status of trial NCT00857350?
This trial is currently completed. The enrollment target is 60 participants. The study started on 2008-06. Estimated completion is 2012-09.
Who is sponsoring clinical trial NCT00857350?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.